NCT05161195
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05161195
Title Roll-over Study to Allow Continued Access to Ribociclib
Recruitment Active, not recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | POL | LBN | ITA | GRC | ESP | BRA | ARG

Facility Status City State Zip Country Details
Ironwood Cancer and Research Centers Chandler Arizona 85224 United States Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
Beverly Hills Cancer Center Beverly Hills California 90211 United States Details
Poudre Valley Hospital Fort Collins Colorado 80528 United States Details
Mid Florida Hematology And Onc Ctr Orange Florida 32763 United States Details
Summit Cancer Care Savannah Georgia 31405 United States Details
John D Archbold Memorial Hospital Thomasville Georgia 31792 United States Details
Duly Health and Care Plainfield Illinois 60585 United States Details
Indian Univ Health Goshen Center forCancer Goshen Indiana 46526 United States Details
Northern Light Mercy Hospital Portland Maine 04102 United States Details
Englewood Health Englewood New Jersey 07631 United States Details
The Valley Hospital-Luckow Pavillion Paramus New Jersey 07652 United States Details
Eastchester Center for Cancer Care The Bronx New York 10469 United States Details
University Hospitals of Cleveland Seidman Cancer Center Cleveland Ohio 44106 United States Details
Oklahoma Cancer Specialists and Research Institute Tulsa Oklahoma 74136 United States Details
Millennium Research Clin Develop Houston Texas 77090 United States Details
Novartis Investigative Site San Juan J5402DIL Argentina Details
Novartis Investigative Site Natal Rio Grande do Norte 59075 740 Brazil Details
Novartis Investigative Site Ijuí Rio Grande do Sul 98700-000 Brazil Details
Novartis Investigative Site Florianópolis Santa Catarina 88020-210 Brazil Details
Novartis Investigative Site São Paulo São Paulo 01317 000 Brazil Details
Novartis Investigative Site São Paulo São Paulo 03102 Brazil Details
Novartis Investigative Site Sao Jose Rio Preto 15090 000 Brazil Details
Novartis Investigative Site São Paulo 01255-000 Brazil Details
Novartis Investigative Site Chongqing Chongqing Municipality 404100 China Details
Novartis Investigative Site Shijiazhuang Hebei 050011 China Details
Novartis Investigative Site Harbin Heilongjiang 150081 China Details
Novartis Investigative Site Changsha Hunan 410013 China Details
Novartis Investigative Site Nanjing Jiangsu 210029 China Details
Novartis Investigative Site Suzhou Jiangsu 215004 China Details
Novartis Investigative Site Changchun Jilin 130021 China Details
Novartis Investigative Site Kunming Yunnan 650106 China Details
Novartis Investigative Site Hangzhou Zhejiang 310006 China Details
Novartis Investigative Site Hangzhou Zhejiang 310016 China Details
Novartis Investigative Site Beijing 100036 China Details
Novartis Investigative Site Qingdao 266000 China Details
Novartis Investigative Site Shanghai 200025 China Details
Novartis Investigative Site Shanghai 200032 China Details
Novartis Investigative Site Tianjin 300480 China Details
Novartis Investigative Site San José 95008 Costa Rica Details
Novartis Investigative Site Heraklion Crete. 715 00 Greece Details
Novartis Investigative Site Hong Kong 999077 Hong Kong Details
Novartis Investigative Site Pokfulam 999077 Hong Kong Details
Novartis Investigative Site Bhubaneshwar Odisha 751007 India Details
Novartis Investigative Site Delhi 110085 India Details
Novartis Investigative Site Meldola FC 47014 Italy Details
Novartis Investigative Site Osaka Osaka 540-0006 Japan Details
Novartis Investigative Site Bunkyo Ku Tokyo 113-8431 Japan Details
Novartis Investigative Site Bunkyo Ku Tokyo 113-8677 Japan Details
Novartis Investigative Site Koto Ku Tokyo 135 8550 Japan Details
Novartis Investigative Site Chouf LBN 1503201002 Lebanon Details
Novartis Investigative Site Beirut 113-0236 Lebanon Details
Novartis Investigative Site Beirut 166830 Lebanon Details
Novartis Investigative Site San Pedro G G 66278 Mexico Details
Novartis Investigative Site Trujillo La Libertad 13011 Peru Details
Novartis Investigative Site San Borja Lima region 41 Peru Details
Novartis Investigative Site Gdansk 80-214 Poland Details
Novartis Investigative Site Lisbon 1400-038 Portugal Details
Novartis Investigative Site Loures 2674-514 Portugal Details
Novartis Investigative Site Porto 4200-072 Portugal Details
Novartis Investigative Site Singapore 119228 Singapore Details
Novartis Investigative Site Cape Town 7500 South Africa Details
Novartis Investigative Site Johannesburg 2196 South Africa Details
Novartis Investigative Site Pretoria 0002 South Africa Details
Novartis Investigative Site Seoul 03080 South Korea Details
Novartis Investigative Site Seoul 03722 South Korea Details
Novartis Investigative Site Sant Joan Despí Barcelona 08970 Spain Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Taipei 11217 Taiwan Details
Novartis Investigative Site Malatya Battalgazi 44280 Turkey (Türkiye) Details
Novartis Investigative Site Diyarbakır Sur 21280 Turkey (Türkiye) Details
Novartis Investigative Site Izmir 35100 Turkey (Türkiye) Details
Novartis Investigative Site Kecioren Ankara 06010 Turkey (Türkiye) Details
Novartis Investigative Site Hanoi 100000 Vietnam Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field